ACP3 and prostate carcinoma: In preclinical prostate cancer models, for example, mRNA vaccines encoding prostate-specific membrane antigen (PSMA) or prostatic acid phosphatase (PAP) have successfully activated cytotoxic T lymphocytes (CTLs) and delayed tumor growth [7].